NHS England has launched a nationwide trial to evaluate a rapid whole‑genome sequencing (WGS) test that can return tumour‑genetic results in just two to three days, instead of the current four‑to‑six‑week wait. The pilot, which analysed samples from 54 children at Addenbrooke’s Hospital, showed that faster diagnosis helped some youngsters avoid invasive surgery altogether, while others received less extensive operations or precision‑medicine approaches.
How the Test Works
Whole‑genome sequencing compares a tumour sample with a sample of the patient’s skin or saliva to spot cellular differences. This comparison reveals why a cancer has developed, identifies the exact disease type and its likely trajectory, and guides clinicians toward the most targeted treatment options. In the study, researchers found that the accelerated WGS delivered the same accuracy as the standard test but in a fraction of the time.
Dr Aditi Vedi, paediatric oncologist at Cambridge University Hospitals, explained the usual delay: “It takes about four to six weeks in reality for the results to come back, and as you can imagine, for childhood cancer we can’t really wait four to six weeks to make treatment decisions.” She added that clinicians often have to rely on multiple other tests to reach the same conclusion.
Real‑Life Benefits for Children
Of the 54 participants, 35 were analysed at diagnosis and roughly half saw their treatment plans improved. Two children with benign tumours avoided any invasive intervention, two others underwent less extensive surgery, and one received precision medicine aimed at a specific gene mutation.
A striking case involved a nine‑year‑old admitted with a collapsed lung. Scans suggested a potentially cancerous mass, but the child was too unwell for a tissue biopsy. Instead, fluid from the chest was sequenced, revealing T‑cell lymphoblastic lymphoma (T‑BL). The rapid result allowed doctors to start appropriate treatment without delay.
Dr Vedi highlighted the human impact: “The most important category for me was the group of patients that didn’t have any treatment, or avoided treatment, or downscaled the treatment that they got as a result of getting their whole genome sequencing back faster.” She noted that avoiding treatment also means sparing children from short‑ and long‑term side‑effects.
Scaling Up Across the NHS
NHS England has backed a national trial that will enrol 200 children over the next two years, aiming to determine whether the rapid test is just as accurate, deliverable, feasible and economically beneficial when rolled out more widely.
The programme will also create a national paediatric genomic network of excellence, bringing together experts to refine the technology and build a research database. Dr Vedi stressed equity: “We’re keen not to have a postcode lottery and have children outside of Cambridgeshire access this technology as well.” Funding from NHS England will support the expansion so that children across the country can benefit from rapid sequencing.
Looking ahead, she said the network will allow researchers to mine data for future insights: “We’re going to develop a database which we can then mine for future research… The patients who are participating in this network of excellence will not only benefit from the network themselves, but will also benefit future patients through creating this library.”
Why it Matters
Speeding up genetic diagnosis transforms the experience of children facing cancer, turning weeks of anxiety into days of clarity and enabling care that is both less invasive and more precise. By reducing waiting times, the test not only spares young patients from unnecessary surgery and its associated trauma but also opens the door to therapies that target the exact genetic drivers of their disease. If the national trial confirms the health‑economic benefits, the NHS could make this rapid sequencing a standard offering, ensuring that every child, regardless of where they live, receives the fastest, most informed start to their treatment journey.
